IMNM

SEC source: 0001993684-26-000008 · form4-09152026_040933.xml · derivative · entry 7

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,840

Underlying: Common Stock · 18,000 shares

Expires 2032-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001993684-26-000008 · form4-09152026_040933.xml · nonDerivative · entry 3

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,250

SEC source: 0001993684-26-000008 · form4-09152026_040933.xml · nonDerivative · entry 2

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,050

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.

SEC source: 0001993684-26-000008 · form4-09152026_040933.xml · nonDerivative · entry 1

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001808343-26-000010 · form4-08122026_090856.xml · nonDerivative · entry 3

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,211

F5 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2026.

SEC source: 0001808343-26-000010 · form4-08122026_090856.xml · nonDerivative · entry 2

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

F4 · price: The weighted average sale price for the transaction report was $26.23, and the range of prices were between $26.00 and $26.48, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001808343-26-000010 · form4-08122026_090856.xml · nonDerivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 62,291

F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

F2 · price: The weighted average sale price for the transaction report was $26.07, and the range of prices were between $26.005 and $26.14, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001808343-26-000009 · form4-08102026_040801.xml · nonDerivative · entry 2

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 72,416

F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

F4 · price: The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001808343-26-000009 · form4-08102026_040801.xml · nonDerivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 87,664

F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

F2 · price: The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001831215-26-000005 · form4-08062026_100833.xml · derivative · entry 5

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,750

Underlying: Common Stock · 40,250 shares

Expires 2035-07-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the options vested on July 29, 2026, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001831215-26-000005 · form4-08062026_100833.xml · derivative · entry 4

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,542

Underlying: Common Stock · 50,366 shares

Expires 2034-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001831215-26-000005 · form4-08062026_100833.xml · nonDerivative · entry 3

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

F2 · price: The weighted average sale price for the transaction report was $25.09, and the range of prices were between $25.00 and $25.295, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001831215-26-000005 · form4-08062026_100833.xml · nonDerivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,616

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001831215-26-000005 · form4-08062026_100833.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,366

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001167496-26-000005 · form4-07272026_040701.xml · derivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,000

Underlying: Common Stock · 360,000 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001167496-26-000005 · form4-07272026_040701.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 870,704

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002026600-26-000002 · form4-07272026_040711.xml · derivative · entry 2

Tsai Philip · CIK 0002026600 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,500

Underlying: Common Stock · 76,500 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0002026600-26-000002 · form4-07272026_040711.xml · nonDerivative · entry 1

Tsai Philip · CIK 0002026600 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,550

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001994071-26-000006 · form4-07272026_040705.xml · derivative · entry 2

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,500

Underlying: Common Stock · 94,500 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001994071-26-000006 · form4-07272026_040705.xml · nonDerivative · entry 1

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,287

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001831215-26-000004 · form4-07272026_040712.xml · derivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001831215-26-000004 · form4-07272026_040712.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,250

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001831144-26-000002 · form4-07272026_040709.xml · derivative · entry 2

Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,500

Underlying: Common Stock · 76,500 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001831144-26-000002 · form4-07272026_040709.xml · nonDerivative · entry 1

Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,805

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001993684-26-000006 · form4-07272026_040707.xml · derivative · entry 5

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,500

Underlying: Common Stock · 76,500 shares

Expires 2036-07-22

F3 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001993684-26-000006 · form4-07272026_040707.xml · nonDerivative · entry 1

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,250

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001997584-26-000006 · form4-07272026_040703.xml · derivative · entry 2

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 108,000 shares

Expires 2036-07-22

F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001997584-26-000006 · form4-07272026_040703.xml · nonDerivative · entry 1

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,805

F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

SEC source: 0001808343-26-000007 · form4-07072026_110744.xml · nonDerivative · entry 2

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 108,504

F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

F4 · price: The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001831215-26-000002 · form4-07092026_090734.xml · derivative · entry 3

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,908

Underlying: Common Stock · 1,092 shares

Expires 2034-08-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001831215-26-000002 · form4-07092026_090734.xml · nonDerivative · entry 2

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.

SEC source: 0001831215-26-000002 · form4-07092026_090734.xml · nonDerivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001808343-26-000007 · form4-07072026_110744.xml · nonDerivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 125,410

F1 · kind: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

F2 · price: The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001808343-26-000005 · form4-07032026_120754.xml · nonDerivative · entry 3

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 208,504

F1 · kind: The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.

F8 · price: The weighted average sale price for the transaction report was $23.33, and the range of prices were between $23.03 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F7 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001808343-26-000005 · form4-07032026_120754.xml · nonDerivative · entry 2

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 232,839

F1 · kind: The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.

F6 · price: The weighted average sale price for the transaction report was $22.35, and the range of prices were between $22.015 and $23.015, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F7 · ownership.nature: ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001997584-26-000004 · form4-07072026_090711.xml · derivative · entry 5

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 290,000

Underlying: Common Stock · 55,000 shares

Expires 2033-10-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001997584-26-000004 · form4-07072026_090711.xml · nonDerivative · entry 4

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,805

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.

F4 · price: The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001997584-26-000004 · form4-07072026_090711.xml · nonDerivative · entry 3

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,877

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.

F3 · price: The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001997584-26-000004 · form4-07072026_090711.xml · nonDerivative · entry 2

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,091

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.

F2 · price: The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001997584-26-000004 · form4-07072026_090711.xml · nonDerivative · entry 1

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001808343-26-000005 · form4-07032026_120754.xml · nonDerivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · See footnotes

Disclosed balance after: 308,504

F1 · kind: The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.

F2 · shares: The shares were sold as follows: 100,000 shares were sold by ABHMC and 1,050 shares were sold ABV II-B.

F3 · price: The weighted average sale price for the transaction report was $21.12, and the range of prices were between $20.83 and $21.47, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F4 · ownership.nature: The shares of Issuer common stock held by the Reporting Person prior to the transaction reported herein reflect pro rata distributions in kind for no additional consideration, effected by each of Arsenal Bridge Venture II LLC ("ABV II") and ABV II-B to their respective members, including ABHMC, the managing member of ABV II and ABV II-B. The receipt of such shares by the Reporting Person constituted a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16, including Rule 16a-13. Following this transaction, ABHMC owns the remaining 308,504 shares of Issuer common stock.

F5 · ownership.nature: The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC and is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABV II-B. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

SEC source: 0001997584-26-000002 · form4-06292026_080646.xml · derivative · entry 4

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 345,000

Underlying: Common Stock · 55,000 shares

Expires 2033-10-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001997584-26-000002 · form4-06292026_080646.xml · nonDerivative · entry 3

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,805

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.

F3 · price: The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001997584-26-000002 · form4-06292026_080646.xml · nonDerivative · entry 2

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,225

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.

F2 · price: The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001997584-26-000002 · form4-06292026_080646.xml · nonDerivative · entry 1

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,805

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001994071-26-000004 · form4-06172026_090615.xml · derivative · entry 3

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2033-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option is fully vested.

SEC source: 0001994071-26-000004 · form4-06172026_090615.xml · nonDerivative · entry 2

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,037

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

F2 · price: The weighted average purchase price for the transaction report was $18.23, and the range of prices were between $17.95 and $18.66, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001994071-26-000004 · form4-06172026_090615.xml · nonDerivative · entry 1

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001808343-26-000002 · form4-06122026_090628.xml · derivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,897

Underlying: Common Stock · 9,897 shares

Expires 2036-06-09

F1 · shares: Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities.

F2 · derivative.exercise_date: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Barchas' continuous service with the Company on each respective vesting date.

SEC source: 0001908755-26-000001 · form4-06122026_090629.xml · derivative · entry 1

SWAIN SANDRA M · CIK 0001908755 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,897

Underlying: Common Stock · 9,897 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.